<DOC>
	<DOC>NCT02153281</DOC>
	<brief_summary>The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution volume (VT), after phenelzine treatment and if so to what extent.</brief_summary>
	<brief_title>Detecting Central and Peripheral Biomarkers in MDD</brief_title>
	<detailed_description>Subjects will receive a PET and MRI scan before and after treatment with phenelzine.</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Phenelzine</mesh_term>
	<criteria>1880 years of age good physical health Diagnostic and Statistical Manual of Mental Disorders (DSMIV) diagnosis of current major depressive episode (MDE) DSMIV diagnosis of major depressive disorder (MDD) verified by SCID for DSMIV and a psychiatric consultation greater than 17 on the 17 item HDRS (Hamilton Depression Rating Scale). history of nonresponse to several different antidepressant classes herbal, drug or medication use (that affect CNS function) suicide attempts drug or medication use within eight weeks (+5 half lives of medication) history of substance abuse or any neurotoxin use history of psychotic symptoms history of central nervous system (CNS) medical illness current substance abuse test positive on pregnancy test (for women)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Positron Emission Tomography (PET)</keyword>
	<keyword>MAO-B</keyword>
</DOC>